前沿生物：FB7013已提交中国IND申报，FB7011处于临床前阶段

Core Viewpoint - Frontline Bio is advancing its pipeline with multiple self-developed projects targeting significant areas such as metabolic diseases, with a focus on innovative dual-target mechanisms to address limitations of existing therapies [2] Pipeline Development - FB7013 has submitted an IND application in China, while FB7011 is in the preclinical stage, with plans to advance both products through preclinical research, IND applications, and clinical work in China [2] - The company is progressing with FB7023 (targeting atherosclerotic cardiovascular disease, ASCVD) and FB7033 (targeting metabolic-associated fatty liver disease, MASH), both currently in preclinical research [2] Research and Data Dissemination - The company aims to actively advance efficacy, pharmacology, and safety studies for FB7023 and FB7033, planning to present data at global high-profile academic conferences to validate academic value and enhance product influence and international attention [2] Business Development Cooperation - The company maintains an open attitude towards collaboration, with a recent partnership with GSK enhancing brand visibility; future collaborations will be based on clinical value and differentiation analysis of each product [2]